{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:29:17Z","timestamp":1781303357304,"version":"3.54.1"},"reference-count":77,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,3,4]]},"DOI":"10.1080\/13543784.2025.2473060","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T15:39:43Z","timestamp":1741275583000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["A focused report on IFN-1 targeted therapies for lupus erythematosus"],"prefix":"10.1080","volume":"34","author":[{"given":"Anushka","family":"Bhatt","sequence":"first","affiliation":[{"name":"Northwell Health","place":["Great Neck, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramiti","family":"Gupta","sequence":"additional","affiliation":[{"name":"University of Texas","place":["Austin, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["Great Neck, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Vashistha","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["Great Neck, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"e_1_3_5_3_1","volume-title":"StatPearls","author":"Justiz Vaillant AA","year":"2023","unstructured":"Justiz Vaillant AA, Goyal A, Varacallo M. Systemic lupus erythematosus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535405\/"},{"key":"e_1_3_5_4_1","volume-title":"Systemic lupus erythematosus","author":"Lahita RG","year":"2010","unstructured":"Lahita RG, Tsokos GC, Buyon JP, et al. Systemic lupus erythematosus. 5th ed. Introduction; 2010.","edition":"5"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197907053010102"},{"key":"e_1_3_5_6_1","volume-title":"Systemic lupus erythematosus","author":"Crow MK","year":"2004","unstructured":"Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. In: Systemic lupus erythematosus. 5th ed. 2004.","edition":"5"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew427"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319885447"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374994-9.10005-1"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.190107"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01604-z"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology12020285"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8442"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050248"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737711"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1823"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.9.4465"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404719"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00275"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124466"},{"issue":"10","key":"e_1_3_5_22_1","first-page":"781","article-title":"FRI0204\u2005SAFETY, TOLERABILITY, PHARMACOKINETIC and PHARMACODYNAMIC EFFECT of BIIB059, a MONOCLONAL ANTIBODY TARGETING BDCA2 FOLLOWING ADMINISTRATION of SUBCUTANEOUS SINGLE DOSES in JAPANESE HEALTHY VOLUNTEERS","volume":"71","author":"Musselli C","year":"2019","unstructured":"Musselli C, Gaudreault F, Himanshu N, et al. FRI0204\u2005SAFETY, TOLERABILITY, PHARMACOKINETIC and PHARMACODYNAMIC EFFECT of BIIB059, a MONOCLONAL ANTIBODY TARGETING BDCA2 FOLLOWING ADMINISTRATION of SUBCUTANEOUS SINGLE DOSES in JAPANESE HEALTHY VOLUNTEERS. Arthritis Rheumatol. 2019;71(suppl 10):781. Available from: https:\/\/acrabstracts.org\/abstract\/safety-tolerability-pharmacokinetic-and-pharmacodynamic-effect-of-biib059-a-monoclonal-antibody-targeting-bdca2-following-administration-of-subcutaneous-single-doses-in-japanese-healthy-volunters\/","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5743"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118025"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118024"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology12020285"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8442"},{"key":"e_1_3_5_28_1","unstructured":"Treatment and prevention of acute lung injury (ALI) in patients with COVID-19 infection - full text view. ClinicalTrials.Gov identifier: nCT04526912. (2021 December 17). Accessed 2025 Jan 30."},{"key":"e_1_3_5_29_1","unstructured":"Study of daxdilimab for the treatment of moderate-to-severe alopecia areata - full text view. ClinicalTrials.Gov identifier: NCT05368103. 2023 May 26 [cited 2025 Jan 30]."},{"key":"e_1_3_5_30_1","unstructured":"A phase 2 proof of concept study to evaluate the efficacy and safety of Daxdilimab in participants with dermatomyositis (DM) or anti-synthetase inflammatory myositis (ASIM) - full text view. ClinicalTrials.Gov identifier: nCT05669014. (2023 May 26). Accessed 2025 Jan 30."},{"key":"e_1_3_5_31_1","unstructured":"Study of daxdilimab (HZN-7734) in participants with active proliferative lupus nephritis (LN) - full text view. ClinicalTrials.Gov identifier: nCT05540665. (2023b May 24). Accessed 2025 Jan 30."},{"key":"e_1_3_5_32_1","unstructured":"Study of daxdilimab (HZN-7734) in patients with moderate-to-severe primary discoid lupus erythematosus - full text view. ClinicalTrials.Gov. Identifier: nCT05591222 (2023 May 8). Accessed 2025 Jan 30."},{"key":"e_1_3_5_33_1","unstructured":"Horizon Therapeutics plcHorizon Therapeutics plc. Horizon therapeutics plc announces phase 2 trial evaluating daxdilimab for the treatment of systemic lupus erythematosus (SLE) did not meet primary endpoint. BioSpace. (2023 July 21).2023 Jul 21 [cited 2025 Jan 29]. Available from: https:\/\/www.biospace.com\/horizon-therapeutics-plc-announces-phase-2-trial-evaluating-daxdilimab-for-the-treatment-of-systemic-lupus-erythematosus-sle-did-not-meet-primary-endpoint"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2004.24.687"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2015.09.058"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064890"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2013.0118"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102502200"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2004.03.003"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.05.001"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30187"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206090"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000261"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000087"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4492"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1912196"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41598"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221847"},{"key":"e_1_3_5_52_1","unstructured":"Center for Drug Evaluation and Research. Drug trials snapshots: saphnelo. U.S. Food and Drug Administration; 2023 Jul 18. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-saphnelo"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(21)00387-8"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac138"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222748"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212504"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42392"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.09.009"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3722"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.4331\/wjbc.v13.i1.1"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y"},{"key":"e_1_3_5_65_1","article-title":"U.S. food and drug administration approves Sotyktu\u2122 (deucravacitinib), oral treatment for adults with moderate-to-severe plaque psoriasis","author":"Brisol Myers Squibb","year":"2022","unstructured":"Brisol Myers Squibb. U.S. food and drug administration approves Sotyktu\u2122 (deucravacitinib), oral treatment for adults with moderate-to-severe plaque psoriasis. Corporate News Details; 2022. https:\/\/news.bms.com\/news\/details\/2022\/U.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis\/default.aspx","journal-title":"Corporate News Details"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13435"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16740"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd5318"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.5020a"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.114"},{"key":"e_1_3_5_74_1","unstructured":"Long-term safety and efficacy study of deucravacitinib in participants with systemic lupus erythematosus - full text view. ClinicalTrials.Gov identifier: nCT03920267. (2023b February 8). Accessed 2025 Jan 30."},{"key":"e_1_3_5_75_1","unstructured":"A study to evaluate efficacy and safety of Deucravacitinib in participants with active discoid and\/or subacute cutaneous lupus erythematosus (Dle\/scle) - full text view. ClinicalTrials.Gov identifier: NCT04857034. 2023 May 23 [cited 2025 Jan 30]."},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02414-0"},{"key":"e_1_3_5_78_1","unstructured":"Anifrolumab (Saphnelo). CADTH reimbursement review: therapeutic area: systemic lupus erythematosus [internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Apr. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596620\/"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2473060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T09:11:12Z","timestamp":1743757872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2473060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"alternative-id":["10.1080\/13543784.2025.2473060"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2473060","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}